Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 143, Issue 1, Pages 16-26Publisher
WILEY
DOI: 10.1111/j.1365-2141.2008.07275.x
Keywords
bleeding; thrombopoietin; thrombopoiesis; chronic immune thrombocytopenic purpura; platelet
Categories
Funding
- Dana Hammond Stubgen
- Children's Cancer and Blood Foundation
- NIH [U01 HL072186]
Ask authors/readers for more resources
There is currently no consensus on how best to manage refractory immune thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment due to the wide spectrum of patients' requirements and responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article suggests investigations to identify factors that may exacerbate thrombocytopenia and underlie poor therapeutic responses, and highlights emerging therapies, including the thrombopoietic agents, which are anticipated to dramatically alter the natural history of refractory ITP. Morbidity, mortality and heath-related quality of life are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available